Healx is a Cambridge, UK-based company passionate about finding new therapeutic solutions for rare diseases. The company uses advanced data analytics, including machine learning and modern computational biology techniques to identify novel drug applications in the area of rare disorders.
Their unique model places patient advocacy groups at the heart of the drug discovery process, leading the way to personalized medicine for rare diseases.
Listed in 2017 as a ‘Leading Global Innovator’ in Disrupt 100 and awarded ‘Cambridge Graduate Startup of the Year’ in 2016, Healx is considered as one of the leading startups of the Cambridge cluster.
In the media
26th July 2018
Healx raises $10m as investors back AI to find rare disease treatments faster
Cambridge, UK – 26th July, 2018 – Healx (https://healx.io), the Cambridge (UK) technology company developing breakthrough treatments for rare diseases, today announced a $10 million Series A funding round, led by Balderton Capital, Europe's leading early-stage venture investor. Existing investors, Jonathan Milner and Amadeus Capital Partners also participated in the round.
6th December 2018
Abcam deputy chairman Jonathan Milner buys 06 December 2018
Horizon Discovery Group plc, The Evolution Education Trust, Repositive Ltd, Syndicate Room Group Ltd and HealX. He is also Chairman of Axol Bioscience
29th November 2018
2018 – The year the pharma industry felt AI’s impact and potential
Other companies, such as Exscientia and Healx (also UK-based), have been reported to have made similar advances for different therapeutic uses. The use of AI in drug discovery is already